{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:01:19Z","timestamp":1791219679700,"version":"4.1.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073818"],"award-info":[{"award-number":["82073818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ60439"],"award-info":[{"award-number":["2023JJ60439"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atezolizumab combined with either bevacizumab (atezo-beva) or cabozantinib (atezo-cabo) has been granted approval for the treatment of advanced hepatocellular carcinoma (HCC). Given the current uncertainty among physicians and patients regarding the optimal choice between these two strategies, it becomes imperative to conduct a cost-effectiveness analysis to compare their relative benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assessing the cost-effectiveness of atezo-beva compared to atezo-cabo in the treatment of advanced HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Both the network treatment comparison and cost-effectiveness analysis included patients from the IMbrave150 and the COSMIC-312 phase 3 randomized clinical trials. The network treatment comparison which included 761 patients was carried out, and a cost-effectiveness analysis that included 487 patients was conducted by developing a Markov model, both between February and November 2020. The robustness of the model was assessed via one-way and probabilistic sensitivity analyses. life-years, quality-adjusted life-years (QALYs), overall costs, and incremental cost-effectiveness ratios (ICERs) were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the atezo-cabo group, atezo-beva group respectively increased 0.528 life years and 0.365 QALYs, with costs per patient increasing by $506,639, and the ICER was $1,388,052.054 per QALY. The one-way sensitivity analysis results indicated that the hazard ratios of OS and HR of PFS were the most sensitive factors in the model. In probabilistic sensitivity analysis, when the WTP threshold is $150,000 per QALY, the cost-effectiveness probabilities of the atezo-beva group and atezo-cabo group were 7.09% and 92.91% respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings from this cost-effectiveness analysis suggested that, compared to atezo-cabo, atezo-beva brought better OS benefits to advanced HCC patients, but also brought higher economic burden, considering the willingness-to-pay threshold was $150 000 per QALY, atezo-beva was not considered cost-effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0337606","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:30:47Z","timestamp":1764786647000},"page":"e0337606","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Heng","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-1236","authenticated-orcid":true,"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"1","key":"pone.0337606.ref001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"RL Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0337606.ref002","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"F Xu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"pone.0337606.ref003","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.3390\/cancers14184523","article-title":"Immunotherapy and Hepatocellular Cancer: Where Are We Now?","volume":"14","author":"M Valery","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0337606.ref004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40364-022-00406-z","article-title":"Advances of cancer-associated fibroblasts in liver cancer","volume":"10","author":"H Peng","year":"2022","journal-title":"Biomark Res"},{"issue":"4","key":"pone.0337606.ref005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0337606.ref006","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma","volume":"77","author":"R Donne","year":"2023","journal-title":"Hepatology"},{"key":"pone.0337606.ref007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/bs.acr.2020.12.001","article-title":"Systemic therapy of liver cancer","volume":"149","author":"T Demir","year":"2021","journal-title":"Adv Cancer Res"},{"issue":"20","key":"pone.0337606.ref008","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0337606.ref009","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"RK Kelley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0337606.ref010","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"NH Tran","year":"2022","journal-title":"Hepatology"},{"issue":"10","key":"pone.0337606.ref011","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"PR Galle","year":"2021","journal-title":"Future Oncol"},{"issue":"16","key":"pone.0337606.ref012","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jama.2018.11808","article-title":"Defining Value-Based Pricing of Drugs","volume":"320","author":"MS Broder","year":"2018","journal-title":"JAMA"},{"issue":"16","key":"pone.0337606.ref013","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"PB Bach","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"pone.0337606.ref014","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment","volume":"26","author":"A Sutton","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"pone.0337606.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042003","article-title":"Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model","volume":"7","author":"J Ramsberg","year":"2012","journal-title":"PLoS One"},{"key":"pone.0337606.ref016","author":"Training C"},{"issue":"5","key":"pone.0337606.ref017","article-title":"Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis","volume":"4","author":"R Pei","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"pone.0337606.ref018","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"GD Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"pone.0337606.ref019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0266462313000160","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"29","author":"D Husereau","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"pone.0337606.ref020","article-title":"Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma","volume":"4","author":"D Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"pone.0337606.ref021","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/cer-2020-0041","article-title":"Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"9","author":"H Cai","year":"2020","journal-title":"J Comp Eff Res"},{"key":"pone.0337606.ref022","author":"Services C f M a M","year":"2023"},{"issue":"6","key":"pone.0337606.ref023","doi-asserted-by":"crossref","first-page":"669","DOI":"10.6004\/jnccn.2018.7275","article-title":"Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma","volume":"17","author":"E Soto-Perez-de-Celis","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"pone.0337606.ref024","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/liv.14795","article-title":"Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states","volume":"41","author":"F Wen","year":"2021","journal-title":"Liver Int"},{"issue":"22","key":"pone.0337606.ref025","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/cncr.34457","article-title":"Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis","volume":"128","author":"Y Li","year":"2022","journal-title":"Cancer"},{"issue":"14","key":"pone.0337606.ref026","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/cer-2022-0064","article-title":"Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis","volume":"11","author":"P-F Zhang","year":"2022","journal-title":"J Comp Eff Res"},{"key":"pone.0337606.ref027","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling For Health Economic Evaluation","author":"A Briggs","year":"2006"},{"key":"pone.0337606.ref028"},{"key":"pone.0337606.ref029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"pone.0337606.ref030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"MW Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"pone.0337606.ref031","doi-asserted-by":"crossref","first-page":"1103055","DOI":"10.3389\/fimmu.2022.1103055","article-title":"Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis","volume":"13","author":"K Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0337606.ref032","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","article-title":"Disease Burden of Hepatocellular Carcinoma: A Global Perspective","volume":"64","author":"M Sayiner","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"6","key":"pone.0337606.ref033","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1002\/cam4.5440","article-title":"Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer","volume":"12","author":"R Cheng","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0337606.ref034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41573-020-00195-w","article-title":"Trends in oncology drug innovation in China","volume":"20","author":"G Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0337606.ref035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12962-023-00435-x","article-title":"Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China","volume":"21","author":"H Gong","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"pone.0337606.ref036","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/cancers13050931","article-title":"First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis","volume":"13","author":"C-L Chiang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0337606.ref037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4846","article-title":"Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma","volume":"4","author":"X Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"pone.0337606.ref038","doi-asserted-by":"crossref","first-page":"1264417","DOI":"10.3389\/fonc.2023.1264417","article-title":"Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma","volume":"13","author":"C-Y Tseng","year":"2023","journal-title":"Front Oncol"},{"key":"pone.0337606.ref039","article-title":"First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States","volume":"15","author":"K-X Sun","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"pone.0337606.ref040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/14737167.2024.2319607","article-title":"Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore","volume":"24","author":"CE Chee","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0337606.ref041","doi-asserted-by":"crossref","first-page":"891008","DOI":"10.3389\/fphar.2022.891008","article-title":"Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis","volume":"13","author":"L Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0337606.ref042","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/CEOR.S461798","article-title":"Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective","volume":"16","author":"B Schwander","year":"2024","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"pone.0337606.ref043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279786","article-title":"First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis","volume":"18","author":"L Wang","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"pone.0337606.ref044","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/10781552211045013","article-title":"The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma","volume":"28","author":"J Giuliani","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"pone.0337606.ref045","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s12325-022-02101-9","article-title":"Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis","volume":"39","author":"Y Zhu","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0337606.ref046","doi-asserted-by":"crossref","first-page":"13160","DOI":"10.1038\/s41598-020-70207-7","article-title":"Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC","volume":"10","author":"P Cui","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0337606.ref047","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40425-019-0578-0","article-title":"Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)","volume":"7","author":"SI Pai","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"9","key":"pone.0337606.ref048","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","article-title":"Landscape of cancer cell therapies: trends and real-world data","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"pone.0337606.ref049","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/bjs\/znab279","article-title":"Treatment of male breast cancer: meta-analysis of real-world evidence","volume":"108","author":"AP Lin","year":"2021","journal-title":"Br J Surg"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:30:53Z","timestamp":1764786653000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337606"}},"subtitle":[],"editor":[{"given":"Keun-Yeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337606","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}